Advisory Board Member 

Dr Mads Hansen

Mads has significant clinical and business expertise within hematology and oncology as well as a robust clinical experience in planning and execution of clinical trials both from academia and the pharmaceutical industry including real-world evidence projects.

Key Areas Of Expertise
  • In-depth knowledge of hematology and malignant lymphoma
    o Board certified specialist in hematology and medicine
  • Real-World Evidence expertise
    o RWD strategy development
    o Execution support of RWD projects
  • Clinical development plan strategy and design
Before NDA

Mads has been the chairman of the EORTC Lymphoma Group for 3 years and external clinical assessor for the Danish Medicines Agency for more than 10 years doing EMA assessments and participating in EMA Scientific Advice’s for the Danish CHMP member.

He was Head of the Lymphoma and Myeloma Clinic at the University Hospital Rigshospitalet, Department of Hematology, Copenhagen, Denmark for 10 years. Before that he was resident at the Finsen Institute, Departments of Hematology (University Hospitals of Copenhagen and Herlev); the Department of Clinical Chemistry (Hillerød Hospital, Denmark) and consultant at the Department of Oncology and Hematology (Hillerød Sygehus, Hillerød).

Since 2008 he has worked in the pharmaceutical industry as Medical Advisor, Genmab A/S; Medical Advisor, Amgen AB Denmark; Therapeutic Head Oncology, Amgen AB, Nordic & Baltic and Medical Director Denmark and Norway, Amgen AB.

Since 2021 founder and managing director of ZEMA Pharma Consulting.

Between 1999 -2008 Mads has been member of the EORTC Lymphoma Group and Chairman between 2005 – 2008. He was also a member of The Nordic Lymphoma Group 1998-2008.

He has published 46 papers in peer reviewed journals, and is a Doctor of Medical Sciences.

Recent Publications

E Kimby, J Jurlander, C Geisler, H Hagberg, H Holte, T Lehtinen, B Ostenstad, M Hansen, A Osterborg O Linden, C Sundstrøm. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008; 49: 102-12.

C Schöllkopf, KE Smedby, H Hjalgrim, K Rostgaard, IP Jensen, L Vinner, B Glimelius, A Porwit C Sundström, M Hansen, HO Adami, M Melbye. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008; 122: 1885-90.

M Pfreundschuh, M Hensel, E Cavallin-Stahl, R Pettengell, I Vasova, A Belch, M Wolf, J Walewski, Pier-Luigi Zinzani, W Mingrone, S Kvaloy, O Shpilberg, U Jaeger, M Hansen, C Corrado, A Scheliga, M Loeffler and E Kuhnt, for the MabThera International Trial (MInT) Group..The prognostic significance of maximal tumor (bulk) size in young patients with good-prognosis diffuse large B-cell lymphoma treated with CHOP-like chemotherapy with and without rituximab: Analysis of the MabThera International Trial Group (MInT) Study. Lancet Oncol 2008; 9: 435-44.

C Schöllkopf, M Melbye, L. Munksgaard, KE Smedby, K Rostgaard, B Glimelius, G. Roos, M Hansen, HO Adami, H. Hjalgrim. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 2008; 111: 5524-9.

Peter Gimsing, Mads Hansen, Lene M Knudsen, P.Knoblauch, Ib Jarle Christensen, Chean Eng Ooi, Peter Buhl-Jensen. A phase I clinical trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with advanced haematological neoplasia. Eur J Haematol 2008; 81: 170-6

Dr Mads Hansen



Stay up to date

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.